Current principles of management of patients experienced acute cerebral circulation disorder at out-patient stage


Cite item

Full Text

Abstract

Ischemic stroke (IS) is an important medical and social problem due to high level morbidity as well as significant temporary disablement and disability rates in the population. In terms of secondary prevention of IS and patient's quality of life improvement, well-founded pathogenic management of patients experienced acute cerebral circulation disorder at out-patient stage is the most significant and economically justified. Current principles of treatment of patients with IS at out-patient stage based on competent and individualized antihypertensive therapy, lipid-lowering therapy, correction of the manifestations of diabetes mellitus, and antithrombotic therapy. This article provides an overview of the main classes of drugs used for stroke secondary prevention.

References

  1. Инсульт. Диагностика, лечение и профилактика. Руководство для врачей / Под ред. З.А. Суслиной, М.А. Пирадова. М., 2008.
  2. Скворцова В.И., Чазова Е.И., Стаховская Л.В. Вторичная профилактика инсульта. М., 2002. 120 с.
  3. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 2003;34:2741-48.
  4. Group P. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995;108:710-17.
  5. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.
  6. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
  7. Schrader J, Luders S, Kulschewski A, et al., for the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699-703.
  8. Collins R, Armitage J, Parish S, et al., for the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
  9. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
  10. Adams H, et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007;38:1655-711.
  11. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS: UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
  12. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20.
  13. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria: North American Microalbuminuria Study Group. Am J Med 1995;99:497-504.
  14. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993;329:1456-62.
  15. American Diabetes Association. ADA clinical practice recommendations. Diabetes Care 2004;27:S1-S143.
  16. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from proactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke 2007;38:865-73.
  17. Суслина З.А., Танашян М.М., Домашенко М.А. Антитромботическая терапия ишемических нарушений мозгового кровообращения. М., 2009. 224 с.
  18. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial. Lancet Neurol 2007;6:115-24.
  19. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-65.
  20. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008 http://www.eso-stroke.org/recommendations.
  21. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
  22. Visser CA, Kan G, Meltzer RS, et al. Long-term follow-up of left ventricular thrombus after acute myocardial infarction. A two-dimensional echocardiographic study in 96 patients. Chest 1984;86:532-36.
  23. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
  24. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
  25. Farrell B, Godwin J, Richards S, et al. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
  26. The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke: the Dutch TIA Study Group. Stroke 1988;19:512-17.
  27. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE): CAPRIE Steering Committee. Lancet 1996;348:1329-39.
  28. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-28.
  29. Ringleb PA, Bhatt DL, Hirsch AT, et al., for the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35:528-32.
  30. Diener HC, Bogousslavsky J, Brass LM, et al., for the MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-37.
  31. Bhatt D, Fox K, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
  32. Yusuf S, Zhao F, Mehta SR, et al., for theClopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
  33. Diener HC, Darius H, Bertrand-Hardy JM, et al., for the European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001;55:162-63.
  34. Diener H, Davidai G. Dipyridamole and headache. Future Neurology 2007;2:279-83.
  35. PRoFESS: обзор результатов <http://www.medscape.com/viewarticle/574558>.
  36. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2320&mid=1085056570&magid=174&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies